Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
NCT07278479
This study is recruiting at 6 US sites in 6 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of [212Pb]Pb-MP0712, in patients aged ≥18 years with Small Cell Lung Cancer and other locally advanced or metastatic DLL3 positive tumors.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Large Cell Neuroendocrine Carcinoma
- Large Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC)
- Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)
- Small Cell Lung Cancer (SCLC)
- Gastroenteropancreatic NEC (GEP NEC)
- NEC of the Bladder
- Other DLL3 Expressing epNEC
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Molecular Partners AG
- Last updated on ClinicalTrials.gov
- September 22, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Florida · 1
- Moffitt Cancer Center · Tampa, FL
Georgia · 1
- Emory University Hospital · Atlanta, GA
Maryland · 1
- United Theranostics · Glen Burnie, MD
Nebraska · 1
- Nebraska Cancer Specialists · Omaha, NE
New Jersey · 1
- United Theranostics · Princeton, NJ
Ohio · 1
- University Hospitals Cleveland Medical Center · Cleveland, OH
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.